StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

Stock analysts at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Down 25.5 %

Shares of BLPH stock opened at $0.01 on Monday. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The firm has a 50 day moving average of $0.02 and a two-hundred day moving average of $0.03. The stock has a market capitalization of $146,796.00, a PE ratio of -0.01 and a beta of 0.74.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.